Suppr超能文献

XEN凝胶支架植入的结果:一项系统评价和荟萃分析。

The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis.

作者信息

Chen Xuan-Zhu, Liang Zhi-Qiao, Yang Kang-Yi, Lv Kun, Ma Yao, Li Meng-Yang, Wu Hui-Juan

机构信息

Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, College of Optometry, Eye Diseases and Optometry Institute, Peking University People's Hospital, Peking University Health Science Center, Beijing, China.

出版信息

Front Med (Lausanne). 2022 Feb 4;9:804847. doi: 10.3389/fmed.2022.804847. eCollection 2022.

Abstract

PURPOSE

XEN gel stents are used for the treatment of open-angle glaucoma (OAG), including primary and secondary glaucoma that are uncontrolled by previous medical therapy and cases with previous failed surgery. Our aim was to systematically review of the clinical data of currently published ab-interno XEN gel stents with an emphasis on intraocular pressure (IOP), antiglaucoma medication outcomes, and safety profiles.

METHODS

We analyzed all of the publications (MEDLINE, EMBASE, Cochrane Library) on the ab-interno XEN gel stent to evaluate the reduction in IOP and antiglaucoma medications following the procedure. The primary outcomes measured for the meta-analysis were reduction in IOP and anti-glaucoma medications. The secondary outcome were adverse events. For each study, we used a random effects analysis model to calculate the mean difference and 95% confidence intervals for the continuous results (reduction in IOP and antiglaucoma medications) using the inverse variance statistical method.

RESULTS

Five hundred twenty-seven articles were checked and 56 studies were found to be relevant with a total of 4,410 eyes. There was a significant reduction in IOP as well as in the number of medications required in patients treated with ab-interno XEN implant either alone or combined with cataract surgery. This new treatment for various types of glaucoma reduced the IOP by 35% to a final average close to 15 mmHg. This reduction was accompanied by a decrease in the number of antiglaucoma medications in all the studies, approximately 2 classes of medication at the price of more needlings. The overall complete success rate was 21.0-70.8% after 2 years using strict criteria originally designed to record success rate in filtration surgery. The incidence of complications vision-threatening was low at <1%.

CONCLUSIONS

XEN gel stent was effective and safe for primary and secondary OAG. Further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation.

摘要

目的

XEN凝胶支架用于治疗开角型青光眼(OAG),包括经既往药物治疗无法控制的原发性和继发性青光眼以及既往手术失败的病例。我们的目的是系统回顾目前已发表的经内路XEN凝胶支架的临床数据,重点关注眼压(IOP)、抗青光眼药物治疗效果和安全性。

方法

我们分析了所有关于经内路XEN凝胶支架的出版物(MEDLINE、EMBASE、Cochrane图书馆),以评估该手术后眼压降低情况和抗青光眼药物使用情况。荟萃分析测量的主要结局是眼压降低和抗青光眼药物使用减少。次要结局是不良事件。对于每项研究,我们使用随机效应分析模型,采用逆方差统计方法计算连续结果(眼压降低和抗青光眼药物使用减少)的平均差异和95%置信区间。

结果

共检索了527篇文章,发现56项研究相关,涉及4410只眼。单独使用经内路XEN植入物或联合白内障手术治疗的患者眼压以及所需药物数量均有显著降低。这种针对各种类型青光眼的新治疗方法使眼压降低了35%,最终平均接近15 mmHg。在所有研究中,这种降低伴随着抗青光眼药物数量的减少,以更多针刺为代价,大约减少了2类药物。按照最初设计用于记录滤过手术成功率的严格标准,2年后总体完全成功率为21.0% - 70.8%。威胁视力的并发症发生率较低,<1%。

结论

XEN凝胶支架对原发性和继发性开角型青光眼有效且安全。应进一步开展研究,以调查种族因素对XEN植入术后成功率和失败率的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bf/8854748/9b746131eca0/fmed-09-804847-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验